semaglutide swisschems FDA warns companies over unapproved weight loss drug sales Semaglutide | CAS 910463-68-2 |

Common side effects (5% or more of patients) Nausea Diarrhea Vomiting Constipation Abdominal pain Reduced appetite Indigestion or acid reflux Fatigue Mild injection site reactions (redness, itching, or bruising) Serious side effects (rare but require immediate medical attention) Pancreatitis: severe, persistent abdominal pain that may radiate to the back, often with nausea or vomiting Gallbladder problems: upper right abdominal pain, fever, jaundice, or unusual stool color Severe allergic reactions: rash, swelling of the face or throat, difficulty breathing Kidney issues: often related to dehydration from prolonged vomiting or diarrhea Diabetic retinopathy complications in patients with pre-existing diabetic eye disease (a known risk specific to rapid A1C reduction) Severe hypoglycemia when used in combination with insulin or sulfonylureas Increased heart rate at rest Boxed warning: Semaglutide caused thyroid C-cell tumors in animal studies

Understanding Semaglutide and Liraglutide Semaglutide and Liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists commonly used to treat type 2 diabetes and assist with weight loss in individuals struggling with obesity or being overweight

The manufacturer liability ends

I always tell patients at baseline to expect some nausea or vomiting the day after injecting, but it should never be debilitating, says Dr